26 reports

  • 1.1 Colorectal Cancer

Most colorectal cancers are due to old age and lifestyle factors with only a small number of cases with underlying genetic disorders.

  • Colorectal Cancer
  • United States
  • Forecast
  • Epigenomics AG
  • Exact Sciences Corp.
  • 05. Introduction
  • 06.1 Understanding the Disease

The risk factors for colorectal cancer include an unhealthy lifestyle, age, genetic disorders, family history, and inflammatory bowel disease.

  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck Serono S.A.

Looking at disease at the genetic and molecular level has, in effect, created new categories of disease.

  • Colorectal Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

Looking at disease at the genetic and molecular level has, in effect, created new categories of disease.

  • Colorectal Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.
  • Disease overview

The risk factors for this cancer include age, family history, unhealthy lifestyle, genetic disorders, and inflammatory bowel disease.

  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sanofi S.A.

" The results from our genetic testing of various cancer markers provides strong evidence of a positive effect against aggressive tumor types, like pancreatic cancer.

  • Biopharmaceutical
  • Colorectal Cancer
  • United States
  • World
  • Product Initiative

THROUGH MASSIVELY PARALLEL SEQUENCING, THIS TECHNOLOGY BRINGS ABOUT FASTER IDENTIFICATION OF GENETIC DISEASES IN SPECIFIC POPULATIONS OR TISSUE TYPES.

  • Colorectal Cancer
  • Molecular Diagnostics
  • North America
  • United States
  • Roche Group

Unlike many " recreational" consumer genetic tests currently available in Asia, these are medical evidence-based genetic tests designed to help physicians screen, diagnose and manage genetic disorders.

  • Colorectal Cancer
  • Genetic Testing
  • East Asia
  • Market Size
  • PerkinElmer, Inc.
  • FEB 09, 2017: ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2017

Phase ## trial results in pediatric patients with neurofibromatosis type ## (NF##) and plexiform neurofibromas published in the New England Journal of Medicine In a Phase ## clinical trial of selumetinib, a MEK inhibitor, children with the common genetic

  • Biopharmaceutical
  • Colorectal Cancer
  • Pharmaceutical
  • United States
  • BioPharma company

Ongoing research suggests genetic mutations could play a role in glioblastoma development.

  • Breast Cancer
  • Colorectal Cancer
  • Epidemiology
  • Therapy
  • Product Initiative

PerkinElmer' s products find applications in early detection of genetic disorders, infectious disease testing, diagnosis of metabolic disorders, cancer treatment, drug discovery and other research activities.

  • Colorectal Cancer
  • Genetic Testing
  • Australia
  • Market Size
  • Illumina, Inc.

Report covers products from therapy areas Oncology, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Fragile X Syndrome, Inflammation, Metastatic Colorectal Cancer and Non-Small C

  • Colorectal Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • eFFECTOR Therapeutics, Inc.
  • ONCOFISH COLORECTAL - PRODUCT DESCRIPTION
  • VERACODE - COLORECTAL CANCER DIAGNOSTIC TESTS - PRODUCT STATUS

Clinical genetic test volume(##) increased by ##. ##% year over year.

  • Clinical Trial
  • Colorectal Cancer
  • Drug Development
  • United States
  • Company

Report covers products from therapy areas Oncology and Genetic Disorders which include indications Diffuse Large B-Cell Lymphoma, Fragile X Syndrome, Head And Neck Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor and Transition

  • Colorectal Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • eFFECTOR Therapeutics, Inc.

Ninety-three percent (## percent) have disease control; one patient has a partial response, one patient has progressive disease, and ## patients have stable disease.

  • Colorectal Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

XBiotech has sought to avoid the use of antibodies derived from mice, genetically modified animals, or from antibodies engineered using modifications to change binding characteristics.

  • Colorectal Cancer
  • Pharmaceutical
  • Europe
  • World
  • XBiotech Inc.
  • COLORECTAL CANCER - PIPELINE BY INTEZYNE TECHNOLOGIES INC
  • COLORECTAL CANCER - PIPELINE BY GENOSCIENCE PHARMA

THE COMPANY PRIMARILY FOCUSES ON RARE GENETIC DISORDERS, KIDNEY DISEASES, ORTHOPEDICS, ORGAN TRANSPLANT, CANCER, AND IMMUNE DISEASE.

  • Colorectal Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative
  • Merck & Co., Inc.

Melanoma is one of the fastest growing cancers worldwide and when diagnosed early, it is generally a curable disease.

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • United States
  • Novartis AG

Melanoma is one of the fastest growing cancers worldwide and when diagnosed early, it is generally a curable disease.

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • United States
  • Novartis AG

IT IS PRODUCED IN GENETICALLY ENGINEERED CHINESE HAMSTER OVARY CELLS.

  • Cancer
  • Colorectal Cancer
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company
  • METASTATIC COLORECTAL CANCER - PIPELINE BY GENZYME CORP, H2 2016

The company' s products and services focuses on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease.

  • Colorectal Cancer
  • Research And Development
  • United States
  • Company
  • Merck & Co., Inc.

CYTOCELL®: FLUORESCENCE IN SITU HYBRIDISATION (FISH) PROBES FOR DETECTING GENE REARRANGEMENTS RELATED TO INHERITED GENETIC DISEASE AND CANCER.

  • Colorectal Cancer
  • In Vitro Diagnostics
  • Lung Cancer
  • Molecular Diagnostics
  • Company

Ltd. has promising clinical drug candidates for ## major therapeutic areas, Oncology, Respiratory, Genito Urinary System And Sex Hormones, Dermatology, Toxicology and Genetic Disorders.

  • Chemotherapy
  • Colorectal Cancer
  • Pharmaceutical
  • Product Initiative
  • Taiho Pharmaceutical Co., Ltd.

The company' s products and services focuses on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease.

  • Colorectal Cancer
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.

IT AIMS TO DEVELOP A MORE PERSONALIZED FORM OF MEDICINE BY PROVIDING THERANOSTICS IN THE AREAS OF INFECTIOUS DISEASES, CANCER AND OTHER GENETIC DISEASES.

  • Colorectal Cancer
  • North America
  • United States
  • Market Size
  • Roche Group

Lozano is a Pediatric Geneticist, who has dedicated his research to better understanding the molecular basis of genetic disorders associated with intellectual disabilities and autism spectrum disorders (ASD).

  • Breast Cancer
  • Cancer
  • Colorectal Cancer
  • Diagnostics
  • Courtagen Life Sciences, Inc.